Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice

Archives of Virology

Volumn 160, Issue 10, 2015, Pages 2517-2524

  Guan, Jie ^a,b   Deng, Yao ^b   Chen, Hong ^b   Yin, Xiao ^b   Yang, Yang ^b   Tan, Wenjie ^b  

^a Meitan General Hospital   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HEPATITIS VACCINE; NS3 PROTEIN, HEPATITIS C VIRUS; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN;

ANIMAL; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DENDRITIC CELL; FEMALE; GENETICS; HEPACIVIRUS; HEPATITIS C; HUMAN; IMMUNIZATION; IMMUNOLOGY; MOUSE; VIROLOGY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; MICE; MICE, INBRED BALB C; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, DNA; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84942504919     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-015-2535-7     Document Type: Article

References (38)

1. Lavanchy D (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107–115
2. Shi C, Ploss A (2013) Hepatitis C virus vaccines in the era of new direct-acting antivirals. Expert Rev Gastroenterol Hepatol 7:171–185
3. Lange CM, Zeuzem S (2013) Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 58:583–592
4. Chatterji U, Garcia-Rivera JA, Baugh J, Gawlik K, Wong KA, Zhong W, Brass CA, Naoumov NV, Gallay PA (2014) The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance. Antimicrob Agents Chemother 58(6):3327–3334
5. Everson GT, Sims KD, Rodriguez-Torres M, Hézode C, Lawitz E, Bourlière M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol S, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF (2014) Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 146(2):420–429
6. Houghton M (2011) Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 239:99–108
7. Neumann-Haefelin C, Thimme R (2013) Adaptive immune responses in hepatitis C virus infection. Curr Top Microbiol Immunol 369:243–262
8. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (2014) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. doi:10.1002/hep.27259
9. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, Eichenlaub D, Pape GR (1995) Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346(8981):1006–1007
10. Habersetzer F, Baumert TF, Stoll-Keller F (2009) GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther 11(4):456–462
11. Mikkelsen M, Holst PJ, Bukh J, Thomsen AR, Christensen JP (2011) Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. J Immunol 186(4):2355–2364
12. Abdulhaqq SA, Weiner DB (2008) DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 42(1–3):219–232
13. Barouch DH (2006) Rational design of gene-based vaccines. J Pathol 208:283–289
14. Hsu KF, Hung CF, Cheng WF, He L, Slater LA, Ling M, Wu TC (2001) Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 8(5):376–383
15. Kim TW, Hung CF, Juang J, He L, Hardwick JM, Wu TC (2004) Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death. Gene Ther 11(3):336–342
16. Boscardin SB, Hafalla JCR, Masilamani RF, Kamphorst AO, Zebroski HA, Rai U, Morrot A, Zavala F, Steinman RM, Nussenzweig RS, Nussenzweig MC (2006) Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 203(3):599–606
17. Nchinda G, Kuroiwa J, Oks M, Trumpfheller C, Park CG, Huang Y, Hannaman D, Schlesinger SJ, Mizenina O, Nussenzweig MC, Uberla K, Steinman RM (2008) The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 118(4):1427–1436
18. Grossmann C, Tenbusch M, Nchinda G, Temchura V, Nabi G, Stone GW, Kornbluth RS, Uberla K (2009) Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands. BMC Immunol 10:43
19. Yin X, Wang W, Tan WJ, Deng Y, Guan J, Wen B, Chen H, Ruan L (2011) Enhancement of the immune response in mice with a noval HCV DNA vaccine targeting NS3 to dendritic cells. Bing Du Xue Bao 27(1):44–49
20. Draper SJ, Heeney JL (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbial 8:62–73
21. Tatsis N, Ertl HC (2004) Adenoviruses as vaccine vectors. Mol Ther 10:616–629
22. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O’Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P (2012) Novel adenovirus-basedvaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4:115ra111
23. Guan J, Wen B, Deng Y, Zhang K, Chen H, Wu X, Ruan L, Tan W (2011) Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes. Virol J 4(8):506
24. Guan J, Deng Y, Chen H, Yang Y, Wen B, Tan W (2014) Immunogenicity and heterologous protection in mice with a recombinant adenoviral-based vaccine carrying a hepatitis C virus truncated NS3 and core fusion protein. Bing Du Xue Bao (in press)
25. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O’Hara GA, Ewer KJ, Anagnostou N, Bliss C, Hill AV, Traboni C, Klenerman P, Cortese R, Nicosia A (2012) Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4:115ra112
26. Folgori A et al (2006) A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 12:190–197
27. Matsui M, Moriya O, Akatsuka T (2003) Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine 21(15):1629–1639
28. Arribillaga L, de Cerio AL, Sarobe P, Sarobe P, Casares N, Gorriaiz M, Vales A, Bruna-Romero O, Borras-Cuesta F, Paranhos-Baccala G, Prieto J, Ruiz J, Lasarte JJ (2002) Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine 21(3–4):202–210
29. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ (2003) Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA 100(11):6753–6758
30. Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, Truitt DM, Kishko MG, Arthur JC, Miura A, Mascola JR, Letvin NL, Nabel GJ (2005) A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 79:8828–8834
31. Yin X, Lu J, Tan W (2010) Enhancement of the immune response of a novel DNA vaccine encoding conserved NS3 and Core fusion gene of HCV injected by intradermal electrotransfer in mice. Chin J Microbiol Immunol 30:41–45
32. Chen H, Wen B, Deng Y, Wang W, Yin X, Guan J, Ruan L, Tan W (2011) Enhanced effect of DNA immunization plus In Vivo electorporation with a combination of Hepatitis B Virus Core-PreS1 and S-PreS1 plasmids. Clin Vaccine Immunol 18:1789–1795
33. Verstrepen BE, Verschoor EJ, Fagrouch ZC, Mooij P, de Groot NG, Bontrop RE, Bogers WM, Heeney JL, Koopman G (2014) Strong vaccine-induced CD8 T-cell responses have cytolytic function in a chimpanzee clearing HCV infection. PLoS One 9(4):e95103
34. Ahlén G, Holmström F, Gibbs A, Alheim M, Frelin L (2014) Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination. Gene Ther. 21(8):739–750
35. http://www.clinicaltrials.gov/ct2/show
36. Lang Kuhs KA, Ginsberg AA, Yan J, Wiseman RW, Khan AS, Sardesai NY, O’Connor DH, Weiner DB (2012) Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]. Mol Ther 20(3):669–678
37. Ip PP, Boerma A, Regts J, Meijerhof T, Wilschut J, Nijman HW, Daemen T (2014) Alphavirus-based vaccines encoding nonstructural proteins of hepatitis C virus induce robust and protective T-cell responses. Mol Ther 22(4):881–890
38. Fournillier A, Frelin L, Jacquier E, Ahlén G, Brass A, Gerossier E, Holmström F, Broderick KE, Sardesai NY, Bonnefoy JY, Inchauspé G, Sällberg M (2013) A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus. J Infect Dis 208(6):1008–1019